SPEEDX/ROCHE
16.6.2020 14:02:13 CEST | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics, in a non-exclusive agreement to expand global access to SpeeDx infectious disease and antibiotic resistance tests and technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005203/en/
“This agreement is a significant inflection point for our company and will enable more patients and clinicians around the world to access key diagnostic tools for the management of antibiotic resistance,” said Colin Denver, SpeeDx CEO. “Our innovative diagnostic tests go beyond simple pathogen detection and support Resistance Guided Therapy – providing information on antibiotic resistance to empower clinicians with the information they need to make appropriate treatment decisions.”
Rising rates of antibiotic resistance are a serious global problem. New, technologically advanced diagnostics help clinicians choose the best targeted therapy for individual patients based on the resistance status of their infection. This helps conserve certain treatment options to better control the spread of resistant infections.1
SpeeDx offers diagnostics tests for the sexually transmitted infections (STIs) gonorrhea and Mycoplasma genitalium (Mgen). These STIs are now listed by the Centers for Disease Control and Prevention (CDC) as key threats due to the concerning rise of resistance and the limited available treatment options.2 Disease management guidelines around the world now focus on the use of resistance identifying diagnostics to help inform treatment.3-7
“The agreement with SpeeDx will allow Roche Diagnostics to provide clinicians with important new tools for detecting antibiotic resistance in patients with sexually transmitted infections," said Mario Torres, Head of Roche Molecular Diagnostics.
Under the terms of the agreement, Roche will have non-exclusive access to SpeeDx existing tests and technology - to enable global access and expansion of diagnostic products for the management of antibiotic resistance in STIs, and quickly bring new products to a broader group of patients.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
References
- https://www.who.int/antimicrobial-resistance/global-action-plan/en/
- https://www.cdc.gov/drugresistance/biggest-threats.html
- Jensen JS, Cusini M, Gomberg M, Moi H. 2016. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. PMID: 27505296.
- https://www.bashhguidelines.org/media/1146/ngu-update-05_2017-final.pdf
- http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
- https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections/canadian-guidelines-sexually-transmitted-infections-49.html
- https://www.sfdermato.org/site/groupe-infectiologie-dermatologique-et-infections-sexuellement-transmissibles.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program1.7.2026 13:55:00 CEST | Press release
Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule API and HPAPI, announced today that AGC has successfully completed an onsite assessment of its new Barcelona facility using the VERIF.i® supplier pre-assessment program. The newly expanded Barcelona site strengthens AGC’s position as a global leader in the development and commercialization of complex small molecule Active Pharmaceutical Ingredients (APIs) and highly potent APIs (HPAPIs). Designed for maximum flexibility, safety, and energy efficiency, the facility expands AGC’s end-to-end capabilities from gram-scale to ton-scale production under the highest quality and sustainability standards. “At AGC Pharma Chemicals, we place the highest priority on the integrity of our operational processes and the expertise of our frontline teams,” said Jun Kurihar
Introducing Arbex: a New Global Leader in Tissue and Hygiene1.7.2026 13:37:00 CEST | Press release
$3.4 billion joint venture between Suzano and Kimberly-Clark launches independent operations and reveals key corporate details Upon launch, Arbex becomes one of the world’s largest tissue and hygiene businesses, operating across more than 70 markets on five continents, with its headquarters in the Netherlands and an operational office in London. The company will produce and sell leading global and regional brands including Kleenex®, Scott®, Cottonelle®, Andrex®, and Viva®, with 22 manufacturing sites in 14 countries. Ehab Abou-Oaf, previously President of International Family Care & Professional at Kimberly-Clark, will directly transition in as Arbex’s CEO, with the role to be based in the United Kingdom alongside the majority of the global executive team. Arbex, a new global leader in tissue and hygiene, today commences operations as an independent business and unveils details of its brand, leadership team, and company structure. Announced in June 2025 as a $3.4 billion joint venture
Klarna has received a favorable ruling in PriceRunner litigation, awarding damages of $1.97 billion1.7.2026 13:19:00 CEST | Press release
Klarna Group plc (NYSE: KLAR) today announces that the court has ruled in PriceRunner’s favor, awarding $1.97 billion in damages in an antitrust case brought by PriceRunner against Google. The award compensates for lost revenue caused by Google's preferential treatment of its own comparison-shopping service over independent price-comparison services, conduct that also drives up costs for consumers. "When markets work well, everyone benefits. Consumers get higher quality at lower cost, companies stay focused on serving customers rather than defending position, and society is better off for it. This ruling supports a healthier, more competitive market for the way people compare products and services — and that is good for everyone who shops," said Dan Greaves, Head of Communications and Policy, Klarna. Klarna acquired PriceRunner in 2022 to add rich product discovery, price comparisons, and product reviews to the Klarna app, and drive high-intent traffic to retail partners. Klarna has si
Objectway Acquires Swiss Private Banking Technology Business From FNZ to Strengthen Its Pan-European Positioning1.7.2026 13:10:00 CEST | Press release
The acquisition consolidates its pan-European footprint, by expanding in Switzerland and Liechtenstein, as well as creating opportunities to expand in other international wealth centres. The investment enhances Objectway’s core-to-digital banking capabilities and strengthens its end-to-end offering for private banks and their cross-border wealth business.Key takeaways Objectway strengthens its positioning in Switzerland and in key international cross-border wealth management hubs. The acquisition enhances Objectway’s end-to-end private banking proposition for mid-sized to large institutions, leveraging core banking expertise and scalable digital solutions. Objectway extends international operational footprint across Switzerland, Singapore and Tunisia, accelerating its growth strategy and reinforcing its ability to support banks facing cross-border expansion, consolidation, regulatory pressure and increasing operational complexity. Objectway, a global wealthtech partner for banking, wea
NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom